Merck & Co. Inc.

12/03/2021 | Press release | Distributed by Public on 12/03/2021 17:19

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection